Medivir announces that development of the HCV nucleotide polymerase inhibitor AL-704 was terminated by Janssen
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the development of AL-704 (also known as JNJ-54257099) has been terminated following completion of phase I clinical studies conducted by Alios Biopharma Inc., one of the Janssen Pharmaceutical Companies. These studies demonstrated that AL-704 was safe, well tolerated and had acceptable pharmacokinetic properties. However its clinical antiviral activity in persons infected with HCV genotype 1 was insufficient to justify further clinical studies. No further compounds arising from Medivir’s license agreement with